Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections
Open Access
- 12 June 2025
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (7) , e0138224
Abstract
Telavancin is an intravenously administered lipoglycopeptide antibiotic active against clinically relevant gram-positive pathogens. In these analyses, a population pharmacokinetic (PK) model was constructed to describe the time course of telavancin in plasma and epithelial lining fluid (ELF) using data from healthy subjects and patients with complicated skin and skin-structure infections, hospital-acquired and ventilator-associated bacterial pneumonia, or uncomplicated bacteremia across Phases 1–4 of clinical development. Data from 1,205 individuals pooled from 21 studies contributed a total of 9,088 telavancin plasma concentrations. The final model for telavancin was a two-compartment model with zero-order intravenous input and linear elimination. Dialysis clearance was included as part of the base structural PK model; the relationship between telavancin clearance and creatinine clearance was included a priori . Body weight, age, and infection type were identified as statistically significant predictors of the interindividual variability (IIV) in total clearance. Body weight, age, and infection type were also identified as statistically significant predictors of IIV for the central and peripheral volumes of distribution. Only body weight was found to be a significant predictor of the IIV in distributional clearance. The model for ELF did not reveal any appreciable biases and determined the average free-drug ELF penetration ratio to be 73.0%. In summary, the population PK model characterized the time course of telavancin in both plasma and ELF robustly, captured the impact of clinically meaningful patient covariate effects, including removal of drug due to hemodialysis, and provided reliable individual post hoc estimates of exposure in subjects enrolled in the clinical studies.Keywords
This publication has 22 references indexed in Scilit:
- Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysisJournal of Antimicrobial Chemotherapy, 2021
- Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram InfusionAntimicrobial Agents and Chemotherapy, 2019
- Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal FunctionAntimicrobial Agents and Chemotherapy, 2012
- Penetration of Vancomycin into Epithelial Lining Fluid in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2011
- Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive PathogensClinical Infectious Diseases, 2011
- Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2008
- Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjectsJournal of Antimicrobial Chemotherapy, 2008
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive OrganismsClinical Infectious Diseases, 2008
- Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005